Reuters logo
BRIEF-Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant
November 27, 2017 / 8:09 AM / 21 days ago

BRIEF-Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant

Nov 27 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd:

* BIOHAVEN COMPLETES ENROLLMENT IN SECOND PIVOTAL PHASE 3 CLINICAL TRIAL OF ORAL CGRP-RECEPTOR ANTAGONIST RIMEGEPANT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below